2
766
Helvetica Chimica Acta ± Vol. 86 (2003)
in Dragendorff tests. F 2' (petroleum ether/AcOEt 9.5:0.5; 90.0 mg) was purified by prep. TLC (petroleum
ether/AcOEt 8.5:1.5) to give 5,10(15)-cadienen-4-ol (1.9 mg). F 3' (petroleum ether/AcOEt 9.2 :0.8; 45.0 mg)
mainly gave piperine in petroleum ether/AcOEt (7.5:2.5). F 4' (petroleum ether/AcOEt 9.0 :1.0; 457 mg) gave
pipzorine (2; 10.7 mg) after prep. TLC on repeated elution with petroleum ether/AcOEt 7.5:2.5). F 6'
(
petroleum ether/AcOEt 8.9 :1.1; 137 mg) was purified on a small column (petroleum ether > petroleum ether/
AcOEt > AcOEt) to obtain 50 fractions (F1'' to F 50''). F 39'' (petroleum ether/AcOEt 6.0 :4.0) was pure
piptahsine (3; 5.3 mg) obtained as flowers of needles.
Oxidative Cleavage of 2. A soln. of 2 (1 mg) in dioxane (0.25ml) and H
2 4
O (0.15ml) was treated with OsO
(
0.3 mg), followed by addition of NaIO (2.5mg) at 25 8. After stirring for 2 h at r.t., the mixture was
4
2
concentrated using a Sep-Pak diol cartridge (Waters). The sample was then eluted with Et O and subjected to
GC and GC/MS analysis.
Hydrolysis of 2. Compound 2 (5mg) was heated at 100 8 for 2 d with EtOH (0.5ml) and conc. HCl (0.5ml)
in a sealed tube. On cooling, the hydrochloride of (4-methylpentyl)amine separated out as fine needles, which,
on liberation with NH OH and usual workup, gave the free amine as a colorless liquid identified by GC and GC/
4
MS analysis. (3-Methylbutyl)- and (2-methylpropyl)amine for co-injection were purchased from Merck; (4-
methylpentyl)amine was prepared from isocapronitrile (see below).
Reduction of Isocapronitrile. To a cooled (ice-bath) soln. of LiAlH
isocapronitrile (12.5g) in anh. Et O (20 ml) was slowly added, and stirring was continued for 75min. The
mixture was diluted with H O (4 ml), and 20% aq. NaOH soln. (3 ml) was added. The etheral soln. was
decanted from the white, granular inorganic residue. This residue was washed twice with Et O, and the
combined org. phases were washed, dried (Na SO ), and evaporated at r.t. to afford (4-methylpentyl)amine
21].
Absolute Configuration of 3 According to Horeau×s Procedure. Pipthasine (2 mg) was added to a soln. of
racemic 2-phenylbutanoic anhydride (0.1 ml) in pyridine (0.5ml). The resulting mixture was stirred for several h
at r.t. and left overnight. It was then poured over distilled H O (0.3 ml), and the mixture was allowed to stand at
r.t. for 30 min. An aq. soln. of NaOH (0.1m) was added dropwise, until the pH was 9.0. The soln. was extracted
with CHCl , the aq. layer was acidified to pH 3 with HCl (1m) and extracted with benzene (10 ml). The benzene
extract was dried (Na SO ) and evaporated to a volume of 1 ml. The optical rotation of the resulting 2-
4 2
(3.8 g) in anh. Et O (200 ml), a soln. of
2
2
2
2
4
[
2
3
2
4
phenylbutanoic acid soln. was measured, which showed a positive value (R)-configuration, thereby establishing
the (S)-configuration at C(4) of 3.
Pipgulzarine ((2E,11E)-12-(Benzo[1,3]dioxol-5-yl)-N-(2-methylpropyl)dodeca-2,11-dienamide; 1). Yel-
low crystals. M.p. 98 ± 1008. IR (KBr): 3343, 2850 ± 2900, 1664, 1612, 1482, 1440, 1400, 1140, 890 ± 860, 840 ± 780.
1
13
UV (MeOH): 313.0 (14,200), 263.4 (5,450). H-NMR and C-NMR data: Table 1. EI-MS: 371 (23.5, M ), 328
(
(
2
(
1
16), 231 (2), 203 (5), 175(10), 161 (99), 135(87), 131 (100), 103 (87), 72 (15), 57 (15.2). HR-EI-MS: 371.2469
M , C23
17.1235([C 14
H
33NO ; calc. 371.2460), 299.1653 ([C19
H
23
O
3
] ), 271.1701 ([C18
H
23
O
2
] ), 245.1547 ([C16
H
21
O
2
] ),
3
H
17
O
2
] ), 210.1861 ([C13
H
24NO
2
] ), 203.1079 ([C13
H
15
O
2
] ), 175.0763 ([C11
H
11
O
2
] ), 161.0610
[C10H
9
O
2
] ), 135.0451 ([C
8
H
7
O
2
] ), 131.0497 ([C
9
H
7
O] ), 126.0923 ([C
7
H
12NO] ), 103.0551 ([C
8
H
7
] ),
00.0767 ([C
5
H
10NO] ), 72.0819 ([C
4
H
10N] ).
Pipzorine ((2E,12Z)-N-(4-Methylpentyl)octadeca-2,12-dienamide; 2). Amorphous powder. IR (KBr):
1
13
3
2
1
450, 1667, 1630. UV (MeOH): 209.5 (6,160). H- and C-NMR data: Table 2. EI-MS 363 (23.5; M ), 334 (71),
92 (23.7), 263 ( 35), 238 (18.2), 181 (21), 167 ( 19), 166 (53), 154 (62), 153 (22), 139 (21), 138 (94), 128 (25),
25 (29), 111 (67), 100 (39), 97 (50), 71 (75), 69 (94), 67(73), 55 (100). HR-EI-MS: 363.3497 (M , C24
H
45NO;
calc. 363.3501), 334.3109 ([C22
H
H
40NO] ), 320.2951 ([C21
32NO] ), 266.2483 ([C17
H
H
38NO] ), 306.2795([C 20
H
H
36NO] ), 292.2639
(
(
9
[C19
[C17
H
34NO] ), 278.2481 ([C18
32NO] ), 263.2371 ([C18
31O] ), 235.2423
H
31] ), 209.2267 ([C15
H
29] ), 154.1229 ([C
9
H
16NO] ), 128.1075([C
7
H
] ).
14NO] ), 100.1126 ([C
6
H
14N] ),
7.1015([C
7
H
13] ), 85.1017 ([C
6
H
13] ), 71.0860 ([C
5
H
11] ), 57.0701 ([C
4
H
9
Piptahsine ((2E,4S)-4-Hydroxy-N-(2-methylpropyl)hex-2-enamide; 3). White needles. M.p. 115± 116 8.
1
13
IR (KBr): 3300 ± 3450, 1676, 1640, 1460 ± 1440, 1100, 980. UV (MeOH): 213.0 (6,965). H- and C-NMR data:
Table 3. EI-MS: 185(33.5; M ), 167 (93), 157 (100), 110 (25), 100 (50), 95 (65), 85 (71), 72 (55), 41 (45). HR-
EI-MS: 185.1410 (M , C10
H
19NO
2
; calc. 185.1415), 167.1304 ([C10
H
17NO] ), 157.1101 ([C
8
H
15NO
2
] ), 139.0991
(
(
(
5
[C
[C
8
H
H
12NO] ), 128.1081 ([C
7
H
14NO] ), 128.0710 ([C
6
H
10NO
2
] ), 126.0911 ([C
NO] ), 100.0757 ([C
O] ), 85.0292 ([C
7
H
H
12NO] ), 114.0551
10NO] ), 100.0401
] ), 72.0809 ([C
5
8
NO
2
] ), 113.0600 ([C
] ), 95.0491 ([C
6
H
9
O
2
] ), 110.0600 ([C
6
H
8
5
[C
4
H
6
NO
2
6
H
7
O] ), 85.0649 ([C
5
H
9
4
H
5
O
2
4
H
10N] ),
7.0701 ([C
4
H
9
] ), 54.0491 ([C
3
H
7
O] ).